Computational Methods in Systems Biology

264 C. Talcott and M. Knapp

References

1. Aksoy, B.A.: BioPax prior information provider (PERA) (2017).http://bit.ly/bp
   prior. Accessed 26 Apr 2017


2. M.D. Anderson Cancer Center: Antibody information and protocols (2017).
   https://www.mdanderson.org/research/research-resources/core-facilities/
   functional-proteomics-rppa-core/antibody-information-and-protocols.html.
   Accessed 25 Apr 2017


3. M.D. Anderson Cancer Center: RPPA core facility (2017). https://
   http://www.mdanderson.org/research/research-resources/core-facilities/
   functional-proteomics-rppa-core.html. Accessed 25 Apr 2017


4. Clavel, M., Dur ́an, F., Eker, S., Lincoln, P., Mart ́ı-Oliet, N., Meseguer, J., Talcott,
   C.: All About Maude - A High-Performance Logical Framework. LNCS, vol. 4350.
   Springer, Heidelberg (2007). doi:10.1007/978-3-540-71999-1


5. Dienstmann, R., Rodon, J., Serra, V., Tabernero, J.: Picking the point of inhibition:
   a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol. Cancer Ther.
   13 (5), 1021–1031 (2014)


6. Donaldson, R., Talcott, C., Knapp, M., Calder, M.: Understanding signalling net-
   works as collections of signal transduction pathways. In: Computational Methods
   in Systems Biology (2010)


7. Fisher, J., Henzinger, T.A.: Executable cell biology. Nat. Biotechnol. 25 (11), 1239–
   1249 (2007)


8. Gujral, T.S., Karp, R.L., Finski, A., Chan, M., Schwartz, P.E., MacBeath, G.,
   Sorger, P.: Profiling phospho-signaling networks in breast cancer using reverse-
   phase protein arrays. Oncogene 32 (29), 3470–3476 (2013)


9. Hill, S.M., et al.: Inferring causal molecular networks: empirical assessment through
   a community-based effort. Nat. Methods 13 (4), 310–318 (2016)


10. Korkut, A., Wang, W., Demir, E., Aksoy, B.A., Jing, X., Molinelli, E.J., Babur,
    O., Bemis, D.L., Onur, S.S., Solit, D.B., Pratilas, C.A., Sander, C.: Perturbation
    biol- ogy nominates upstream-downstream drug combinations in RAF inhibitor
    resistant melanoma cells. Elife 18 (4) (2015). Article id 26284497


11. Logie, L., Ruiz-Alcaraz, A.J., Keane, M., Woods, Y.L., Bain, J., Marquez, R.,
    Alessi, D.R., Sutherland, C.: Characterization of a protein kinase B inhibitor in
    vitro and in insulin-treated liver cells. Diabetes 56 (9), 2218–2227 (2007)


12. Nigam, V., Donaldson, R., Knapp, M., McCarthy, T., Talcott, C.: Inferring exe-
    cutable models from formalized experimental evidence. In: Roux, O., Bourdon, J.
    (eds.) CMSB 2015. LNCS, vol. 9308, pp. 90–103. Springer, Cham (2015). doi:10.
    1007/978-3-319-23401-4 9


13. Pathway Logic (2016).http://pl.csl.sri.com. Accessed 10 Jan 2016


14. Samatar, A.A., Poulikakos, P.I.: Targeting RAS-ERK signalling in cancer: promises
    and challenges. Nat. Rev. Drug Discov. 13 (12), 928–942 (2014)


15. Schmidt, K.: LoLA a low level analyser. In: Nielsen, M., Simpson, D. (eds.)
    ICATPN 2000. LNCS, vol. 1825, pp. 465–474. Springer, Heidelberg (2000). doi:10.
    1007/3-540-44988-4 27


16. Talcott, C.: The pathway logic formal modeling system: diverse views of a formal
    representation of signal transduction. In: Wang, Q. (ed.) Workshop on Formal
    Methods in Bioinformatics and Biomedicine (2016)


17. Tsai, J., et al.: Discovery of a selective inhibitor of oncogenic B-Raf kinase with
    potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 105 (8), 3041–3046
    (2008)